Microvascular heart involvement in systemic autoimmune diseases: The purinergic pathway and therapeutic insights from the biology of the diseases.

[1]  C. Prati,et al.  Microvascular endothelial dysfunction in rheumatoid arthritis , 2018, Nature Reviews Rheumatology.

[2]  T. Mikuls,et al.  State of the Art Review: Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications , 2018 .

[3]  D. Bluemke,et al.  Absence of Fibrosis and Inflammation by Cardiac Magnetic Resonance Imaging in Rheumatoid Arthritis Patients with Low to Moderate Disease Activity , 2018, The Journal of Rheumatology.

[4]  M. Eisenhut,et al.  Cardiovascular involvement in systemic rheumatic diseases: An integrated view for the treating physicians. , 2018, Autoimmunity reviews.

[5]  M. Hickey,et al.  CD39 and CD73 activity are protective in a mouse model of antiphospholipid antibody-induced miscarriages. , 2017, Journal of autoimmunity.

[6]  Nikki A. Hawkins,et al.  Comorbidity Status and Annual Total Medical Expenditures in U.S. Hypertensive Adults , 2017, American journal of preventive medicine.

[7]  C. Masciocchi,et al.  Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic sclerosis patients of recent onset , 2017, International journal of rheumatic diseases.

[8]  V. Willey,et al.  Initiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan , 2017, Journal of the American Heart Association.

[9]  J. Primdahl,et al.  EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update , 2016, Annals of the rheumatic diseases.

[10]  Xuehao Wang,et al.  Human CD39hi regulatory T cells present stronger stability and function under inflammatory conditions , 2016, Cellular &Molecular Immunology.

[11]  M. Sitkovsky,et al.  Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases , 2017, Nature Reviews Rheumatology.

[12]  H. Boshuizen,et al.  Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study , 2016, Rheumatology International.

[13]  S. Robson,et al.  Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[14]  M. Gulliford,et al.  Cardiovascular risk assessment and treatment in chronic inflammatory disorders in primary care , 2016, Heart.

[15]  Y. Shoenfeld,et al.  Autoimmune atherosclerosis in 3D: How it develops, how to diagnose and what to do. , 2016, Autoimmunity reviews.

[16]  E. Matteson,et al.  Drug prescribing trends in adults with rheumatoid arthritis: a population-based comparative study from 2005 to 2014 , 2016, Clinical Rheumatology.

[17]  J. Kaski,et al.  Coronary microvascular dysfunction in chronic inflammatory rheumatoid diseases. , 2016, European heart journal.

[18]  J. Pope,et al.  A review of the effects of statins in systemic sclerosis. , 2016, Seminars in arthritis and rheumatism.

[19]  S. Grieve,et al.  Prevalence, distribution and clinical correlates of myocardial fibrosis in systemic lupus erythematosus: a cardiac magnetic resonance study , 2016, Lupus.

[20]  S. Tiosano,et al.  Coexistence of ischemic heart disease and rheumatoid arthritis patients-A case control study. , 2016, Autoimmunity reviews.

[21]  M. Wasko,et al.  Prevention of cardiovascular disease in rheumatoid arthritis. , 2015, Autoimmunity reviews.

[22]  E. Slominska,et al.  The role of ecto-5′-nucleotidase in endothelial dysfunction and vascular pathologies , 2015, Pharmacological reports : PR.

[23]  Puja K. Mehta,et al.  Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy , 2015, Nature Reviews Cardiology.

[24]  U. Kramer,et al.  Clinical and Histopathological Features of Patients with Systemic Sclerosis Undergoing Endomyocardial Biopsy , 2015, PloS one.

[25]  Yenn-Jiang Lin,et al.  Inflammation and the pathogenesis of atrial fibrillation , 2015, Nature Reviews Cardiology.

[26]  F. Liew,et al.  Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis , 2015, Proceedings of the National Academy of Sciences.

[27]  P. Matthews,et al.  Impaired myocardial perfusion is associated with extracellular volume expansion, disease activity and impaired strain and strain rate in systemic sclerosis: a cardiovascular magnetic resonance study , 2015, Journal of Cardiovascular Magnetic Resonance.

[28]  M. Francone,et al.  Evaluation of early myocardial damage in systemic sclerosis (SSc): a cardiovascular magnetic resonance study , 2015, Journal of Cardiovascular Magnetic Resonance.

[29]  P. Matthews,et al.  Impaired myocardial perfusion in rheumatoid arthritis is associated with impaired strain, strain rate, disease activity and myocardial oedema: a cardiovascular magnetic resonance study , 2015, Journal of Cardiovascular Magnetic Resonance.

[30]  P. Matthews,et al.  Abnormal myocardial perfusion correlates with impaired systolic strain and diastolic strain rate in systemic lupus erythematosus: a cardiovascular magnetic resonance study , 2015, Journal of Cardiovascular Magnetic Resonance.

[31]  J. Reiber,et al.  Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis. , 2015, Inflammation & allergy drug targets.

[32]  Ornella Rimoldi,et al.  Coronary microvascular dysfunction: mechanisms and functional assessment , 2015, Nature Reviews Cardiology.

[33]  Stefan L. Zimmerman,et al.  Myocardial T2 mapping by cardiovascular magnetic resonance reveals subclinical myocardial inflammation in patients with systemic lupus erythematosus , 2015, The International Journal of Cardiovascular Imaging.

[34]  Y. Shoenfeld,et al.  Is atherosclerosis accelerated in systemic sclerosis? Novel insights , 2014, Current opinion in rheumatology.

[35]  A. Catrina,et al.  Surface expression of CD39 identifies an enriched Treg‐cell subset in the rheumatic joint, which does not suppress IL‐17A secretion , 2014, European journal of immunology.

[36]  P. Lazzerini,et al.  Arrhythmic risk in rheumatoid arthritis: the driving role of systemic inflammation. , 2014, Autoimmunity reviews.

[37]  J. Lekakis,et al.  Increased Benefit of Interleukin-1 Inhibition on Vascular Function, Myocardial Deformation, and Twisting in Patients With Coronary Artery Disease and Coexisting Rheumatoid Arthritis , 2014, Circulation. Cardiovascular imaging.

[38]  C. Thongprayoon,et al.  Risk of coronary artery disease in patients with systemic sclerosis: a systematic review and meta-analysis , 2014, Clinical Rheumatology.

[39]  F. Crea,et al.  Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. , 2014, Seminars in arthritis and rheumatism.

[40]  M. Budoff,et al.  Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease , 2013, Annals of the rheumatic diseases.

[41]  L. Chiriboga,et al.  Extracellular generation of adenosine by the ectonucleotidases CD39 and CD73 promotes dermal fibrosis. , 2013, The American journal of pathology.

[42]  M. Wasko,et al.  Cardiovascular disease in autoimmune rheumatic diseases. , 2013, Autoimmunity reviews.

[43]  E. Vizi,et al.  CD39 and CD73 in immunity and inflammation. , 2013, Trends in molecular medicine.

[44]  O. Rimoldi,et al.  Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. , 2013, JACC. Cardiovascular imaging.

[45]  E. Nagel,et al.  Native Myocardial T1 Mapping by Cardiovascular Magnetic Resonance Imaging in Subclinical Cardiomyopathy in Patients With Systemic Lupus Erythematosus , 2013, Circulation. Cardiovascular imaging.

[46]  G. Kitas,et al.  Myocardial ischaemia without obstructive coronary artery disease in rheumatoid arthritis : hypothesis-generating insights from a cross-sectional study , 2012 .

[47]  M. Abrahamowicz,et al.  Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: A population‐based study , 2012, Arthritis care & research.

[48]  J. Zweier,et al.  Transgenic over expression of ectonucleotide triphosphate diphosphohydrolase-1 protects against murine myocardial ischemic injury. , 2011, Journal of molecular and cellular cardiology.

[49]  Li Zhang,et al.  Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures , 2010, Journal of cellular and molecular medicine.

[50]  D. Berman,et al.  Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus. , 2011, JACC. Cardiovascular imaging.

[51]  S. Deaglio,et al.  Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. , 2011, Advances in pharmacology.

[52]  E Picano,et al.  From endothelial dysfunction to atherosclerosis. , 2010, Autoimmunity reviews.

[53]  Y. Allanore,et al.  Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin. , 2010, Clinical and experimental rheumatology.

[54]  E. Feierl,et al.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database , 2010, Annals of the rheumatic diseases.

[55]  D. Gladman,et al.  Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus , 2010, Arthritis care & research.

[56]  Yasuyuki Kobayashi,et al.  Cardiac magnetic resonance imaging abnormalities in patients with systemic lupus erythematosus: a preliminary report , 2010, Modern rheumatology.

[57]  N. Lamblin,et al.  Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients , 2008, Annals of the rheumatic diseases.

[58]  J. Barkhausen,et al.  Detection of Myocardial Fibrosis in Systemic Sclerosis by Contrast-Enhanced Magnetic Resonance Imaging , 2008, RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin.

[59]  Yu Lin,et al.  The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation. , 2007, American journal of physiology. Heart and circulatory physiology.

[60]  C. Ledent,et al.  Cardioprotection by Ecto-5′-Nucleotidase (CD73) and A2B Adenosine Receptors , 2007, Circulation.

[61]  O. Vignaux,et al.  Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. , 2006, The Journal of rheumatology.

[62]  J. F. Chen,et al.  Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. , 2006, Arthritis and rheumatism.

[63]  D. Jue,et al.  Chloroquine inhibits production of TNF-α, IL-1β and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes , 2006 .

[64]  J. Elias,et al.  Partially adenosine deaminase-deficient mice develop pulmonary fibrosis in association with adenosine elevations. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[65]  M. Pillinger,et al.  Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy? , 2006, Arthritis and rheumatism.

[66]  G. Kitas,et al.  Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome , 2005, Annals of the rheumatic diseases.

[67]  I. Bruce.  'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. , 2005, Rheumatology.

[68]  I. Bruce.  Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? , 2005, Best practice & research. Clinical rheumatology.

[69]  B. Cronstein,et al.  Adenosine A2A Receptor Stimulation Increases Angiogenesis by Down-Regulating Production of the Antiangiogenic Matrix Protein Thrombospondin 1 , 2005, Molecular Pharmacology.

[70]  M. J. Broekman,et al.  Role of CD39 (NTPDase-1) in Thromboregulation, Cerebroprotection, and Cardioprotection , 2005, Seminars in thrombosis and hemostasis.

[71]  F. Ruschitzka,et al.  Simvastatin improves endothelial function in patients with rheumatoid arthritis. , 2005, Journal of the American College of Cardiology.

[72]  S. Frøland,et al.  Increased Expression of Interleukin-1 in Coronary Artery Disease With Downregulatory Effects of HMG-CoA Reductase Inhibitors , 2004, Circulation.

[73]  Paolo Raggi,et al.  Premature coronary-artery atherosclerosis in systemic lupus erythematosus. , 2003, The New England journal of medicine.

[74]  J. Schwartz,et al.  Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. , 2003, The New England journal of medicine.

[75]  H. Gabbert,et al.  Diminished Coronary Reserve in Patients with Biopsy-Proven Inflammatory Infiltrates , 2003, Cardiology.

[76]  Single photon emission computed tomography of technetium-99m tetrofosmin myocardial perfusion imaging in patients with systemic lupus erythematosus--a preliminary report. , 2003, Japanese heart journal.

[77]  A. Tenenbaum,et al.  Coronary Artery Disease but Not Coronary Calcification Is Associated with Elevated Levels of Cardiolipin, Beta-2-Glycoprotein-I, and Oxidized LDL Antibodies , 2001, The Cardiology.

[78]  I. Bruce,et al.  Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. , 1999, The Journal of rheumatology.

[79]  R. D'Agostino,et al.  Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. , 1997, American journal of epidemiology.

[80]  L. Magder,et al.  Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. , 1994, The American journal of medicine.

[81]  D. Wallace,et al.  Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. , 1990, The American journal of medicine.

[82]  G. Hutchins,et al.  Myocardial Lesions of Progressive Systemic Sclerosis: A Cause of Cardiac Dysfunction , 1976, Circulation.

[83]  M. Urowitz,et al.  The bimodal mortality pattern of systemic lupus erythematosus. , 1976, The American journal of medicine.